eFFECTOR Therapeutics is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, specializing in the discovery and development of precision oncology therapies. Since its founding in 2015, the company has focused on the modulation of protein synthesis as a novel approach to cancer treatment. By leveraging insights into the regulation of mRNA translation, eFFECTOR aims to address oncogenic drivers that are traditionally considered “undruggable,” providing a complementary strategy to established targeted therapies and immuno-oncology agents.
The company’s lead candidate, eFT226, is a first-in-class small molecule inhibitor of the eukaryotic initiation factor 4A (eIF4A), which plays a critical role in cancer cell protein translation. eFFECTOR’s pipeline also includes earlier-stage programs targeting additional components of the translational machinery, broadening its potential to impact a variety of tumor types. Preclinical studies have demonstrated that these modulators can selectively impair the growth of cancer cells by disrupting the synthesis of oncogenic proteins, offering a promising therapeutic index.
eFFECTOR Therapeutics conducts its research and development activities through a combination of internal labs in the United States and strategic collaborations with academic institutions and industry partners worldwide. The company actively engages in translational research to support biomarker-driven patient selection, aiming to enhance clinical trial design and improve response rates. These partnerships extend across North America, Europe and Asia, reflecting eFFECTOR’s commitment to global oncology innovation.
At the helm of eFFECTOR is CEO Kristiina Vuori, Ph.D., whose leadership is supported by a management team with extensive experience in drug discovery, clinical development and regulatory affairs. The board and scientific advisory group comprise seasoned oncology experts, ensuring robust oversight and strategic guidance. With a focused pipeline and a differentiated scientific approach, eFFECTOR Therapeutics continues to advance its precision oncology platform toward delivering new treatment options for patients with high unmet medical needs.
AI Generated. May Contain Errors.
Free EFTR Stock Alerts